$3.75
-0.02 (-0.53%)
Arena Pharmaceuticals, Inc. (ARNA)
CAPS Rating:
A clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases.
RSS Headlines
Fool UK
Recs
Feeling very confident that Lorcaserin, Arena's anti-obesity drug will receive FDA approval. The Phase III trials have been going well and the independent monitoring of Lorcaserin shows no signs of cardiac heart valve issues. I expect that Arena will have a strategic partner lined up by the end of this year for Lorcaserin. My educated guess is that they are in negotiations with a three or more prospective partners and are looking for the right deal for the partnership. In addition, Arena's pipeline is very compelling with the Insomnia drug now in Phase 2B trials showing well and I expect this to move into Phase III by the end of 2008. If all goes well Arena will have huge upside within the next two years.